InStent EndoCoil biliary stent is awaiting 510(k) clearance -- IPO.
This article was originally published in The Gray Sheet
Executive Summary
INSTENT ENDOCOIL STENT FOR MALIGNANT BILIARY STRICTURES due to pancreatic cancer is awaiting 510(k) clearance by FDA, the firm notes in a registration statement filed with the Securities and Exchange Commission for an initial public offering. The company "has responded to requests from FDA for additional information" on the 510(k) and "is currently awaiting FDA action," the filing states.
You may also be interested in...
Abbott Capitalizes On Pandemic Testing Boom; Device Sales Stay Almost Flat
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
Agios’ Mitapivat Shows Improvement In Regularly Transfused PKD Patients
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.
Medtech Industry Favorite Wins Seat On Powerful House E&C Committee
As a freshman member on the US House Energy and Commerce Committee, former St. Jude Medical exec Rep. Angie Craig can help shape future health care, cybersecurity bills.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: